EUVIMEDEUVIMED entdecken
Open Access

Distinct uptake and elimination profiles for trastuzumab, human IgG, and biocytin-TMR in experimental HER2+ brain metastases of breast cancer

Vanesa L Silvestri iD, Andy D Tran, Monika Chung, Natalie Chung, Brunilde Gril, Christina Robinson, Simone Difilippantonio, Debbie Wei, Michael J Kruhlak, Cody J Peer, W Douglas Figg, Imran Khan und 1 weitere

Neuro-Oncology · 2024

DOI: 10.1093/neuonc/noae025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Vanesa L Silvestri und 12 weiteren Autor:innen. Beteiligte Einrichtung: Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Trastuzumab, Brain Neoplasms, Breast Neoplasms, Immunoglobulin G. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The aim of this study is an improved understanding of drug distribution in brain metastases. Rather than single point snapshots, we analyzed the time course and route of drug/probe elimination (clearance), focusing on the intramural periarterial drainage (IPAD) pathway.

Methods

Mice with JIMT1-BR HER2+ experimental brain metastases were injected with biocytin-TMR and either trastuzumab or human IgG. Drugs/probes circulated for 5 min to 48 h, followed by perfusion. Brain sections were stained for human IgG, vascular basement membrane proteins laminin or collagen IV, and periarterial α-SMA. A machine learning algorithm was developed to identify metastases, metastatic microenvironment, and uninvolved brain in confocally scanned brain sections. Drug/probe intensity over time and total imaged drug exposure (iAUC) were calculated for 27,249 lesions and co-immunofluorescence with IPAD-vascular matrix analyzed in 11,668 metastases.

Results

In metastases, peak trastuzumab levels were 5-fold higher than human IgG but 4-fold less than biocytin-TMR. The elimination phase constituted 85–93% of total iAUC for all drugs/probes tested. For trastuzumab, total iAUC during uptake was similar to the small molecule drug probe biocytin-TMR, but slower trastuzumab elimination resulted in a 1.7-fold higher total iAUC. During elimination trastuzumab and IgG were preferentially enriched in the α-SMA+ periarterial vascular matrix, consistent with the IPAD clearance route; biocytin-TMR showed heterogeneous elimination pathways.

Conclusions

Drug/probe elimination is an important component of drug development for brain metastases. We identified a prolonged elimination pathway for systemically administered antibodies through the periarterial vascular matrix that may contribute to the sustained presence and efficacy of large antibody therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrastuzumabBrain NeoplasmsBreast NeoplasmsImmunoglobulin GErb-b2 Receptor Tyrosine KinasesAnimalsMiceHumansFemaleAntineoplastic Agents, ImmunologicalXenograft Model Antitumor Assays

Stichwörter der Autor:innen

HER2brain metastasisbreast cancerpharmacokinetictrastuzumab

Substanzen

TrastuzumabImmunoglobulin GErb-b2 Receptor Tyrosine KinasesAntineoplastic Agents, ImmunologicalERBB2 protein, human

Autor:innen und Institutionen

  • Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
  • Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
  • CCR Microscopy Core, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
  • Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
  • Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.

ORCID-Profile: Vanesa L Silvestri

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Silvestri, V. L., Tran, A. D., Chung, M., Chung, N., Gril, B., Robinson, C., Difilippantonio, S., Wei, D., Kruhlak, M. J., Peer, C. J., Figg, W. D., Khan, I., & Steeg, P. S. (2024). Distinct uptake and elimination profiles for trastuzumab, human IgG, and biocytin-TMR in experimental HER2+ brain metastases of breast cancer. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae025

Vancouver

Silvestri VL, Tran AD, Chung M, Chung N, Gril B, Robinson C, et al. Distinct uptake and elimination profiles for trastuzumab, human IgG, and biocytin-TMR in experimental HER2+ brain metastases of breast cancer. Neuro-Oncology. 2024. doi:10.1093/neuonc/noae025

BibTeX
@article{Silvestri2024,
  author = {Silvestri, Vanesa L and Tran, Andy D and Chung, Monika and Chung, Natalie and Gril, Brunilde and Robinson, Christina and Difilippantonio, Simone and Wei, Debbie and Kruhlak, Michael J and Peer, Cody J and Figg, W Douglas and Khan, Imran and Steeg, Patricia S},
  title = {Distinct uptake and elimination profiles for trastuzumab, human IgG, and biocytin-TMR in experimental HER2+ brain metastases of breast cancer},
  journal = {Neuro-Oncology},
  year = {2024},
  doi = {10.1093/neuonc/noae025}
}
Kostenlos starten →